Pharmacotherapy of impulse control disorders: A systematic review

Psychiatry Res. 2022 May:311:114499. doi: 10.1016/j.psychres.2022.114499. Epub 2022 Mar 7.

Abstract

There are currently no evidence-based treatment recommendations for impulse control disorders, which include intermittent explosive disorder (IED), kleptomania and pyromania. Therefore, this systematic review sought to identify all randomized controlled trials (RCTs) that investigated pharmacological treatments for impulse control disorders, to evaluate their efficacy and tolerability. Searches were conducted within MEDLINE, PsychINFO, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) databases. Eight studies were included, six investigated pharmacotherapies for IED, while two investigated management for kleptomania. For the treatment of IED, oxcarbazepine and fluoxetine were the most efficacious. Importantly, divalproex was not superior to placebo in decreasing IED symptoms and was associated with significant adverse effects. In the treatment of kleptomania, only naltrexone was effective. The existing data suggest that the pharmacological treatment for impulse control disorders is an understudied area of psychiatry. Much of the current research on impulse control disorders focuses on management with anticonvulsants and antidepressants. Further studies conducted on these interventions in this population may yield promising results.

Keywords: Impulsivity; Intermittent explosive disorder; Kleptomania; Pyromania.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Disruptive, Impulse Control, and Conduct Disorders* / drug therapy
  • Fluoxetine / therapeutic use
  • Humans
  • Valproic Acid

Substances

  • Antidepressive Agents
  • Fluoxetine
  • Valproic Acid